Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Ann Oncol ; 35(2): 190-199, 2024 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-37872020

RESUMO

BACKGROUND: Immune checkpoint inhibitors in combination with tyrosine kinase inhibitors are standard treatments for advanced clear cell renal cell carcinoma (RCC). This phase III RENOTORCH study compared the efficacy and safety of toripalimab plus axitinib versus sunitinib for the first-line treatment of patients with intermediate-/poor-risk advanced RCC. PATIENTS AND METHODS: Patients with intermediate-/poor-risk unresectable or metastatic RCC were randomized in a ratio of 1 : 1 to receive toripalimab (240 mg intravenously once every 3 weeks) plus axitinib (5 mg orally twice daily) or sunitinib [50 mg orally once daily for 4 weeks (6-week cycle) or 2 weeks (3-week cycle)]. The primary endpoint was progression-free survival (PFS) assessed by an independent review committee (IRC). The secondary endpoints were investigator-assessed PFS, overall response rate (ORR), overall survival (OS), and safety. RESULTS: A total of 421 patients were randomized to receive toripalimab plus axitinib (n = 210) or sunitinib (n = 211). With a median follow-up of 14.6 months, toripalimab plus axitinib significantly reduced the risk of disease progression or death by 35% compared with sunitinib as assessed by an IRC [hazard ratio (HR) 0.65, 95% confidence interval (CI) 0.49-0.86; P = 0.0028]. The median PFS was 18.0 months in the toripalimab-axitinib group, whereas it was 9.8 months in the sunitinib group. The IRC-assessed ORR was significantly higher in the toripalimab-axitinib group compared with the sunitinib group (56.7% versus 30.8%; P < 0.0001). An OS trend favoring toripalimab plus axitinib was also observed (HR 0.61, 95% CI 0.40-0.92). Treatment-related grade ≥3 adverse events occurred in 61.5% of patients in the toripalimab-axitinib group and 58.6% of patients in the sunitinib group. CONCLUSION: In patients with previously untreated intermediate-/poor-risk advanced RCC, toripalimab plus axitinib provided significantly longer PFS and higher ORR than sunitinib and had a manageable safety profile TRIAL REGISTRATION: ClinicalTrials.gov NCT04394975.


Assuntos
Anticorpos Monoclonais Humanizados , Carcinoma de Células Renais , Neoplasias Renais , Humanos , Anticorpos Monoclonais Humanizados/uso terapêutico , Axitinibe/uso terapêutico , Carcinoma de Células Renais/tratamento farmacológico , Carcinoma de Células Renais/patologia , Neoplasias Renais/tratamento farmacológico , Sunitinibe/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
2.
Genet Mol Res ; 12(3): 2886-94, 2013 Aug 12.
Artigo em Inglês | MEDLINE | ID: mdl-24065644

RESUMO

Fusion gene expression, a kind of chromosome rearrangement mode, has been strongly linked to prostate cancer diagnosis and prognosis as well as to the Gleason score and the American Joint Committee on Cancer stage assessment. In combination with traditional methods for locating fusion genes and scoring their association with cancer cell growth, proliferation, and invasion through the basement membrane, the emerging high-throughput sequencing technologies offer a panorama of fusion genes in a genome and facilitate the discovery of new fusion modes. We describe here a method for using single-end reads to analyze fusion gene expression in prostate tumors. We obtained the fusion gene expression profiling of prostate tumors, clustered them into several biological pathways, highlighted three "rediscovered" fusion genes (TMPRSS2-ERG, KLK2, and KLK3) and proved the reliability of our method.


Assuntos
Calicreínas/genética , Proteínas de Fusão Oncogênica/genética , Antígeno Prostático Específico/genética , Neoplasias da Próstata/genética , Regulação Neoplásica da Expressão Gênica , Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Hibridização in Situ Fluorescente , Masculino , Gradação de Tumores , Proteínas de Fusão Oncogênica/isolamento & purificação , Prognóstico , Neoplasias da Próstata/patologia
3.
Diabetologia ; 55(11): 2954-62, 2012 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-22886370

RESUMO

AIMS/HYPOTHESIS: Few data are available about intakes and food sources of trans-fatty acids (TFAs) or their associations with cardiometabolic outcomes in Asian people who consume a prudent diet but are experiencing rapid nutritional transitions. We aimed to investigate the relationships between TFA biomarkers and type 2 diabetes and cardiovascular risk factors in Chinese individuals. METHODS: Erythrocyte fatty acids were measured by gas chromatography among 3,107 men and women (50-70 years) recruited from urban and rural areas in Beijing and Shanghai, China. RESULTS: Total trans-18:1 and two trans-18:2 isomers were detected and accounted for 0.37% of the total fatty acids in the erythrocytes. Concentrations of TFAs were higher in women than men, and in urban than rural residents. Of the TFAs, trans-18:1, but not trans-18:2, showed a modest association with dairy consumption (ß = 0.27), but not with other foods. After adjustment for BMI, social-demographic, lifestyle and dietary factors and other TFAs, erythrocyte trans-18:1 was shown to be associated with a lower risk of type 2 diabetes (OR comparing extreme [first and fourth] quartiles 0.68, 95% CI 0.48, 0.97, p(trend) = 0.02), as well as 20-50% lower odds of central obesity, dyslipidaemia, hyperglycaemia, insulin resistance and chronic inflammation. In contrast, trans-18:2 fatty acids were positively associated with high triacylglycerol (p(trend) < 0.001) and LDL-cholesterol (p(trend) = 0.03) levels, but not with diabetes and other cardiometabolic risk factors. CONCLUSIONS/INTERPRETATION: Among middle-aged and older Chinese individuals with overall low erythrocyte TFAs levels, trans-18:1 might serve as a marker of dairy intake. Higher trans-18:1 levels were associated with a lower risk of type 2 diabetes, whereas higher trans-18:2 levels were associated with dyslipidaemia.


Assuntos
Povo Asiático/estatística & dados numéricos , Doenças Cardiovasculares/etnologia , Diabetes Mellitus Tipo 2/etnologia , Dislipidemias/etnologia , Eritrócitos/metabolismo , Ácidos Graxos trans/metabolismo , Adulto , Distribuição por Idade , Idoso , Biomarcadores/metabolismo , Doenças Cardiovasculares/metabolismo , China/epidemiologia , Diabetes Mellitus Tipo 2/metabolismo , Dislipidemias/metabolismo , Comportamento Alimentar , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fatores de Risco , População Rural/estatística & dados numéricos , População Urbana/estatística & dados numéricos
5.
Oncogene ; 36(32): 4610-4618, 2017 08 10.
Artigo em Inglês | MEDLINE | ID: mdl-28368403

RESUMO

Heparin-binding epidermal growth factor (EGF)-like growth factor (HBEGF) is a ligand for the EGF receptor (EGFR), one of the most commonly amplified receptor tyrosine kinases (RTKs) in glioblastoma (GBM). While HBEGF has been found to be expressed in a subset of malignant gliomas, its sufficiency for glioma initiation has not been evaluated. In this study, we demonstrate that HBEGF can initiate GBM in mice in the context of Ink4a/Arf and Pten loss, and that these tumors are similar to the classical GBM subtype observed in patients. Isogenic astrocytes from these mice showed activation not only of Egfr but also the RTK Axl in response to HBEGF stimulation. Deletion of either Egfr or Axl decreased the tumorigenic properties of HBEGF-transformed cells; however, only EGFR was able to rescue the phenotype in cells lacking both RTKs indicating that Egfr is required for activation of Axl in this context. Silencing of HBEGF in vivo resulted in tumor regression and significantly increased survival, suggesting that HBEGF may be a clinically relevant target.


Assuntos
Fator 1 de Ribosilação do ADP/genética , Neoplasias Encefálicas/metabolismo , Carcinogênese/metabolismo , Inibidor p16 de Quinase Dependente de Ciclina/genética , Glioblastoma/metabolismo , Fator de Crescimento Semelhante a EGF de Ligação à Heparina/metabolismo , PTEN Fosfo-Hidrolase/genética , Fator 1 de Ribosilação do ADP/metabolismo , Animais , Astrócitos/patologia , Neoplasias Encefálicas/genética , Neoplasias Encefálicas/patologia , Carcinogênese/genética , Carcinogênese/patologia , Estudos de Coortes , Inibidor p16 de Quinase Dependente de Ciclina/metabolismo , Receptores ErbB/genética , Receptores ErbB/metabolismo , Glioblastoma/genética , Glioblastoma/patologia , Fator de Crescimento Semelhante a EGF de Ligação à Heparina/genética , Humanos , Estimativa de Kaplan-Meier , Camundongos , Camundongos Knockout , PTEN Fosfo-Hidrolase/metabolismo , Receptores Proteína Tirosina Quinases/metabolismo
6.
Zhong Xi Yi Jie He Za Zhi ; 11(3): 135-7, 131, 1991 Mar.
Artigo em Chinês | MEDLINE | ID: mdl-2065389

RESUMO

Among 60 patients with chronic active hepatitis B, 43 were of the severe type, 17 were of cholestasis type. Each type was divided randomly into two groups: therapeutic and control. The former received both conventional supporting therapy and combination of phentolamine (20-30 mg/day) and angelicini (150-450 mg/day). The latter was only treated with conventional supporting therapy. Digital subtraction angiography (DSA) and platelet agglutination test were performed in 10 patients respectively. DSA demonstrated that liver sinusoids were expanded and the vascular bed round the sinusoids were also enlarged in diameter following instillation of phentolamine. It was also shown that angelicini could suppress the second phase of platelet agglutination. These indicated that phentolamine and angelicini could improve the liver microcirculation in different way. The incidence of survival between therapeutic and the control group was 57.14% and 31.82% respectively (P less than 0.05).


Assuntos
Medicamentos de Ervas Chinesas/uso terapêutico , Hepatite B/tratamento farmacológico , Fentolamina/uso terapêutico , Inibidores da Agregação Plaquetária/uso terapêutico , Adulto , Colestase Intra-Hepática/tratamento farmacológico , Quimioterapia Combinada , Feminino , Hepatite Crônica/tratamento farmacológico , Humanos , Circulação Hepática/efeitos dos fármacos , Masculino , Pessoa de Meia-Idade
7.
Appl Opt ; 27(19): 4131-8, 1988 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-20539527

RESUMO

We report on laboratory experiments on single-mode optical fibers for use in measuring earth strain. We have monitored the long-term stability of 25-m long tensioned fibers and found their rates of fractional change in optical path lengths to be no more than 2 x 10(-6)/yr. The optical temperature coefficients for several fibers whose physical lengths were held constant were found to be within 4% of 1.17 x 10(-5) apparent strain/ degrees C. The strain sensitivity (the ratio of observed optical path change to physical path change) was determined to be within 1% of 1.16 for all the fibers tested. Initial field tests indicate that fibers are suitable for earth strain measurements of moderate precision.

8.
J Tongji Med Univ ; 13(2): 116-20, 1993.
Artigo em Inglês | MEDLINE | ID: mdl-7693964

RESUMO

In order to find out the infectious rate of hepatitis C virus (HCV) among chronic liver diseases, we investigated antibodies against hepatitis C virus and HCVRNA by method of ELISA, RIBA and RT-PCR in 410 patients with chronic liver disease. The prevalence of HCV infection was found to be 4%. Whereas the positive rate of HBsAg and HBV-DNA of these cases was 69% and 58%, respectively. There is no statistical significance between HCV infectious rate of patients with positive and negative HBsAg. The relative low infectious rate of HCV infection among chronic hepatic diseases indicates that HBV infection plays a more important role in causing chronic hepatitis than that of HCV. Thus, special emphasis should be paid to the preventive and therapeutic measures against hepatitis B in China.


Assuntos
Hepatite C/epidemiologia , China/epidemiologia , Hepacivirus/genética , Anticorpos Anti-Hepatite/sangue , Hepatite B/epidemiologia , Antígenos de Superfície da Hepatite B/sangue , Anticorpos Anti-Hepatite C , Humanos , Reação em Cadeia da Polimerase , Prevalência , RNA Viral/sangue , DNA Polimerase Dirigida por RNA
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA